Navigation Links
MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
Date:4/15/2008

vivo systems and Phase 1 data in mild to moderate asthmatic volunteers demonstrated the safety and tolerability of the monoclonal antibody, thus supporting its continued development.

About Interleukin-13 (IL-13)

Preclinical data has demonstrated that IL-13 plays an important role in asthma. It is one of at least 29 naturally occurring interleukins in the human body. Overexpression of IL-13 in animal models has been shown to result in many of the features associated with human asthma. IL-13 is believed to be a relevant target for treating asthma, considering its potential role in airway obstruction and in chronic airways remodeling, as seen in animal models.

Clinical Development in Asthma

MedImmune has multiple approaches in development targeting asthma. Currently, in human testing the company has antibodies targeting IL-9 (MEDI 528) and IL-13 (CAT-354), each in Phase 2 development, and an anti-IL-5 receptor (MEDI 563), which is in Phase 1 development. In addition, the company has a number of antibodies that are anticipated to be designated as drug candidates.

About Asthma

Asthma is a chronic disease of the airways that may cause wheezing, breathlessness, chest tightness and coughing. According to the U.S. Centers for Disease Control and Prevention (CDC), more than 30 million Americans reported having a history of asthma in 2003, including nine million children. About 20 million said they currently had asthma. In 2000, the CDC reported that there were more than 10 million asthma-related outpatient visits to private physician offices and hospital clinics. The National Institutes of Health (NIH) have estimated asthma-related healthcare costs in the U.S. at $14 billion annually.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is f
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
2. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
3. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
4. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
5. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
6. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
7. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
8. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  Heated dialogue in recent months about ... cancer treatments to Gilead,s new hepatitis C drug Harvoni® ... world questioning what it means to put a price ... And while drug pricing is one of the ... both a general business and ethical standpoint – it ...
(Date:11/21/2014)... , Nov. 21, 2014 ... the European Medicines Agency (EMA) has granted ... company,s lead product candidate, for the treatment ... a rare, severely disabling genetic disease characterized ... swelling (flare-ups) and new abnormal bone formation. ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... , Chief Executive Officer, will be presenting at the 26 ... York Palace Hotel in New York . ... at 2:00 PM ET. In addition, Mr. Krakauer and ... for separate one-on-one meetings during the day. ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
... IRIDEX Corporation (NASDAQ: IRIX ) today announced that it ... after the market closes on Thursday, March 1, 2012. ... a conference call with the investment community at 5:00 ... 2012 to discuss the results of the quarter and ...
... Medical Corp.,s (Nasdaq Market: ESMC) subsidiary,  Sonomed Escalon™ announced ... AXIS™ Image Management System at the recent World Ophthalmology ... Matthew Carnevale, Chief Technical Officer, stated that ... ophthalmic diagnostic imaging management, and provides an entirely new ...
Cached Medicine Technology:Sonomed Escalon™ Announces Release of AXIS™ iPad App 2Sonomed Escalon™ Announces Release of AXIS™ iPad App 3
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... outcomes are better when patients are treated in an ambulance ... drugs, German researchers report. The sooner patients get the ... the outcome after a stroke, the researchers noted. For the ... first hour after stroke symptoms start, the researchers said. ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 CRN International, ... veteran radio industry sales professional to its award-winning team. ... 30 years of leadership and sales experience to CRN. ... assume the title of Director of Strategy and Development, ... Robert O’Mara. , Heinemann will handle a wide range ...
(Date:11/21/2014)... -- Seeking to make it tougher for people to ... on Thursday approved a new hydrocodone tablet that,s designed ... by the brand name Vicodin -- is a powerful ... in dangerous addictions across the United States. The ... is an extended-release tablet to treat pain severe enough ...
(Date:11/21/2014)... (HealthDay News) -- Scientists say they,ve mapped the genome -- ... British man,s brain, in hopes it might help others with ... the journal Genome Biology , the tapeworm was removed ... ethnicity. "This infection is so rare worldwide and completely ... ... until the worm was pulled out from the brain," ...
(Date:11/21/2014)... Mass. (PRWEB) November 21, 2014 Center ... free workshops titled “Massachusetts Insurance Funding for Autism Workshops” ... (ASD) navigate their way through the insurance coverage process. ... under Massachusetts law and the most effective ways to ... Thursday, Dec. 4 from 6-8:00 p.m. at 331 Montvale ...
Breaking Medicine News(10 mins):Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3Health News:Ick! Tapeworm Infecting Man's Brain Yields Genetic Secrets 2Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2
... A new study shows there is some truth in the ... the brain active. It is long been believed that mental ... the Rush Alzheimer's Disease Centre in the US now reveal ... ongoing Religious Orders Study, involving the cognitive health of older ...
... research has established that a decreased white blood ... aggressive periodontitis.The scientists showed that at six weeks of ... of their alveolar bone whereas the normal mice had ... which anchors teeth in place, is an indication of ...
... said that older hospital patients with delirium run a ... condition. Researchers suggested there's a need for research to ... to investigate interventions that can be made after discharge ... study covered 361 patients aged 65 or older, of ...
... Better health may be only a dash and sprinkel ... found that herbs, in addition to making food tastier, ... potential anticancer benefits when supplementing a balanced diet.Herbs have ... including garlic, the researchers say. Their findings appear in ...
... was found using new technology which helps prevent stroke. One ... by ultrasound, at any blockages in the carotid arteries that ... the US have pioneered the use of a portable device, ... 20 people, this was used to take two different images ...
... measles, mumps and rubella is in short supply. The ... with shortfalls caused by production problems, fewer drugmakers// and ... ,The situation is so bad that 8 of the ... tetanus, diphtheria and a pneumococcal vaccine used to prevent ...
Cached Medicine News:Health News:Herbs: rich soure of antioxidants 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: